Elanco Animal Health (NASDAQ:ELAN) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Elanco Animal Health (NASDAQ:ELAN) have been assigned a consensus recommendation of “Hold” from the fifteen ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $33.15.

A number of research firms recently commented on ELAN. Zacks Investment Research upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a research note on Wednesday. Guggenheim began coverage on Elanco Animal Health in a research note on Wednesday, May 22nd. They issued a “neutral” rating for the company. UBS Group began coverage on Elanco Animal Health in a research note on Wednesday, March 20th. They issued a “sell” rating and a $28.00 price target for the company. Bank of America upgraded Elanco Animal Health from a “neutral” rating to a “buy” rating and set a $30.95 price target for the company in a research note on Monday, March 18th. Finally, Morgan Stanley began coverage on Elanco Animal Health in a research note on Wednesday, March 13th. They issued an “equal weight” rating and a $34.00 price target for the company.

In other Elanco Animal Health news, Director John P. Bilbrey purchased 7,750 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were bought at an average price of $32.39 per share, with a total value of $251,022.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

A number of large investors have recently made changes to their positions in the stock. Primecap Management Co. CA raised its holdings in Elanco Animal Health by 516.8% during the first quarter. Primecap Management Co. CA now owns 30,607,906 shares of the company’s stock worth $981,596,000 after purchasing an additional 25,645,707 shares in the last quarter. BlackRock Inc. raised its holdings in Elanco Animal Health by 618.1% during the first quarter. BlackRock Inc. now owns 19,559,113 shares of the company’s stock worth $627,262,000 after purchasing an additional 16,835,410 shares in the last quarter. Amundi Pioneer Asset Management Inc. raised its holdings in Elanco Animal Health by 84.8% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 10,657,690 shares of the company’s stock worth $341,792,000 after purchasing an additional 4,890,712 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Elanco Animal Health during the first quarter worth approximately $341,261,000. Finally, OppenheimerFunds Inc. bought a new stake in Elanco Animal Health during the first quarter worth approximately $310,058,000.

NASDAQ:ELAN opened at $33.73 on Friday. Elanco Animal Health has a one year low of $28.00 and a one year high of $37.61.

Elanco Animal Health (NASDAQ:ELAN) last posted its quarterly earnings results on Thursday, May 9th. The company reported $0.25 EPS for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.03. The firm had revenue of $731.10 million during the quarter, compared to analyst estimates of $743.40 million. The firm’s revenue for the quarter was down .7% on a year-over-year basis. During the same quarter last year, the business posted $0.33 earnings per share.

Elanco Animal Health Company Profile

There is no company description available for Elanco Animal Health Inc

See Also: Understanding debt-to-equity ratio in fundamental analysis

Analyst Recommendations for Elanco Animal Health (NASDAQ:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.